ADAR1 Capital Management »

Avalo Therapeutics Ord shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Avalo Therapeutics Ord (AVTX) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Avalo Therapeutics Ord

Tip: Access up to 7 years of quarterly data

All positions including Avalo Therapeutics Ord held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Avalo Therapeutics Ord by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $131k 6.0k 21.75

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Avalo Therapeutics Ord

Ikarian Capital
OrbiMed Advisors
RA Capital Management
BVF
Logos Global Management
Commodore Capital
Sio Capital Management
Affinity Asset Advisors
Vanguard Group
Geode Capital Management
Bank of America Corporation
BlackRock
BlackRock
Morgan Stanley
Efficient Wealth Management

View all funds holding Avalo Therapeutics Ord